Key facts
- This page summarizes Joseph S. Zakrzewski's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
- 6 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 23 Mar 2026, 19:07.
Joseph S. Zakrzewski - 19 Mar 2026 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)
- Reporting relationship
- Director
- Issuer ticker
- ANTX
- Reported as of
- 19 Mar 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Mar 2026, 19:07:54 UTC
- Prior SEC filing
- 23 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lucy Day, Attorney-in-Fact for Joseph S. Zakrzewski
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Joseph S. Zakrzewski filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 23 Mar 2026.
Change
- Previous filing in this sequence was filed on 23 Feb 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001331852
Primary reporting owner
Zakrzewski Joseph S
- Relationship
- Director
- Address
- C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK
- Signature
- /s/ Lucy Day, Attorney-in-Fact for Joseph S. Zakrzewski
- Signature date
- 23 Mar 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ANTX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +99,999
- Change %
- Price
- Shares after
- 99,999
- Date
- 19 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 99,999
- Exercise price
- $3.91
- Footnotes
- F1, F2, F3
ANTX
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -99,999
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 99,999
- Exercise price
- $6.60
- Footnotes
- F2, F3
ANTX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +10,362
- Change %
- Price
- Shares after
- 10,362
- Date
- 19 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,362
- Exercise price
- $3.91
- Footnotes
- F1, F2, F3
ANTX
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -10,362
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,362
- Exercise price
- $17.28
- Footnotes
- F2, F3
ANTX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +23,742
- Change %
- Price
- Shares after
- 23,742
- Date
- 19 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,742
- Exercise price
- $3.91
- Footnotes
- F1, F2, F3
ANTX
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -23,742
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,742
- Exercise price
- $5.91
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
Footnote F2
The option is fully vested.
Footnote F3
On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.